Skip to content
MarketScale
‹ Back to IndustriesHealthcare

President Biden’s National Drug Control Strategy

The opioid crisis in the United States is on the rise. Overdose deaths continue to escalate, even with increased measures to curtail illegal access to subscription medication. The CDC estimates annual overdose deaths top 100,000.  On April 21, 2022, President Biden provided Congress with his administration’s first National Drug Control Strategy. The strategy focuses on…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The opioid crisis in the United States is on the rise. Overdose deaths continue to escalate, even with increased measures to curtail illegal access to subscription medication. The CDC estimates annual overdose deaths top 100,000. On April 21, 2022, President Biden provided Congress with his administration’s first National Drug Control Strategy. The strategy focuses on two drivers of the epidemic: untreated addiction and drug trafficking.

 
Eliminating Illegal Drugs Does Not Eliminate Addiction

The President’s Drug Control Strategy proposes several methods for reducing domestic and international drug production and trafficking, including increased border protection and $300 million in the Drug Enforcement Administration’s budget. How much of an impact will these efforts make? It is impossible to determine at present, but Dr. Michael Sprintz, Founder and CEO of the Sprintz Center for Pain, pointed out that even if the United States could eliminate all illegal drugs coming across its borders, drug addiction would not simply go away.

“Eliminating the supply does not change the demand,” said Dr. Michael Sprintz. “We saw this play out as the DEA decreased the availability of prescription opioids, and yet what happened was the demand for opioids from people with addictive disease didn’t decrease.”

Harm reduction efforts are another important component in the fight against addiction, as the availability of fentanyl and other synthetic drugs make overdoses more common and more deadly. In 2020, the U.S. attributed 56,516 overdose deaths to synthetic opioids (primarily fentanyl.) Increasing the availability of life-saving drugs like NARCAN® and safe needle-exchange programs will help save lives. Still, harm reduction efforts do not solve the core problem, which is treating the addiction and getting patients the care they need to recover.

 
It’s Not Just About Getting Access to Care

Increasing access to care is a welcomed part of the Biden plan, but care, in and of itself, is not a total solution. “It’s about having access to evidence-based, affordable care,” Dr. Sprintz said. “You can have access to care to get treatment for a substance abuse problem, but if you can’t afford it, it doesn’t matter that you have access to it.”

Affordable, available, and successful treatment services are paramount to stopping addiction in this country. “If we don’t have treatment services to help people not just get sober, but stay sober, to give them the tools to help them cope with life on life’s terms, then we’re screwed,” Dr. Sprintz said.

The efforts to make more affordable treatment services available to people suffering from addiction is what Dr. Sprintz believes is the most important takeaway from the Biden drug control strategy. “We need to give access to care to as many people as we can and do it in a way that we can afford it.”

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Who's Really Running Healthcare? (When Physicians No Longer Have a Voice) - Dr. Krishna Vedala

Who's Really Running Healthcare? (When Physicians No Longer Have a Voice) - Dr. Krishna Vedala

Physician burnout stems not just from workload but from loss of meaningful voice in healthcare organizations. Dr. Krishna Vedala discusses how primary care is mismanaged as a procedural business, how AI should free physicians from administrative work rather than replace them, and why physicians may need collective representation to restore trust between clinicians and administrators.

  • 01Physicians increasingly lack meaningful participation in organizational decisions, despite being closest to patients and responsible for care delivery.
  • 02Primary care requires complex, nuanced decision-making but is often managed with productivity expectations designed for procedural specialties, pushing work home and some physicians toward breaking point.
  • 03AI's highest value is reducing administrative burden and documentation so physicians have more time with patients, not replacing clinical judgment or human relationships.

Sep 8, 2026

MRI segmentation models can now label 80 structures, but deployment is the hard part

MRI segmentation models can now label 80 structures. TotalSegmentator MRI is an nnU-Net model that provides rapid segmentation of all major organs across all MRI sequences, according to Radiology Business. For health systems, deployment is the hard part.

  • 01The spread between 0.97 Dice on lungs and 0.54 on portal and splenic veins in MRSegmentator is the real operational story: enterprises need confidence flags and escalation paths, not a single headline score.
  • 02Hospitals planning radiation oncology and neuro volumetry programs can treat segmentation speedups as capacity gains only if downstream steps, contour review, dose planning inputs, and reporting templates, are standardized.

Sep 8, 2026

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512